| Description | NU1025 (NSC-696807) is a potent PARP inhibitor with IC50 of 400 nM. |
| In vitro | NU1025 (0.2 mM) treatment attenuates Water2 induced cytotoxicity. NU1025 per se does not have any effect on cell viability. NU1025 pretreatment significantly increases cell viability (82.59 4.67%) in SIN-1 (0.8 mM) exposed cells.[2] NU1025 has no detectable effect on the proliferation of D54 and U251 cells. Treatment with NU1025 markedly inhibits the enhanced activation of PARP-1 induced by TPT and RT treatment.[3] No DNA strand breakage is detected following exposure to 200 μM NU1025 alone.[4] |
| In vivo | 使用NU1025（1和3 mg/kg）处理，与对照组大鼠相比，可将梗塞面积减少至25%和45%。NU1025（1和3 mg/kg）治疗显著减少了水肿体积。此外，NU1025还显著改善了神经功能缺损。[2] |
| Cell experiments | Cells are seeded in 96-well plates at a density of 2,500 cells/well and treated with the indicated doses of NU1025. Adherent cells are irradiated in medium with 250 kVp X-rays (dose rate 0.5 Gy/min). Untreated cells are used as a control. Following an up to 5 day incubation, cell proliferation is assessed by MTT assay.(Only for Reference) |
| Target activity | PARP:400 nM |
| Synonyms | NSC 696807 |
| molecular weight | 176.17 |
| Molecular formula | C9H8N2O2 |
| CAS | 90417-38-2 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 40 mg/mL (227.05 mM), Sonication is recommended. 1eq. NaOH: 17.6 mg/mL (100 mM) |
| References | 1. McCabe N, et al. Cancer Biol Ther. 2005, 4(9), 934-936. 2. Kaundal RK, et al. Life Sci. 2006, 79(24), 2293-2302. 3. Sabbatino F, et al. Cytometry A. 2014, 85(11), 953-961. 4. Bowman KJ, et al. Br J Cancer. 2001, 84(1), 106-112. |